Profile data is unavailable for this security.
About the company
Surgical Science Sweden AB is a Sweden-based company, which provides with virtual reality simulators for evidence based laparoscopic and endoscopic training. The systems comprise LapSim, EndoSim and TeamSim trainings. Each training combine graphics and cognitive instruction, imply navigation on touch screens and feature tactile feedback technology. The LapSim trainings consist of laparoscopic exercises that range from basic navigation to advanced suturing, the EndoSim endoscopic exercises range from functions of the scope handle and tube, to loop reduction. The TeamSim comprises procedure modules to train in a real world operation room environment and helps to build team communication skills in crisis and routine situations. The training systems are used by medical training centers and institutes worldwide for practice, validation and certification of students, surgeons, and medical doctors.
- Revenue in SEK (TTM)882.85m
- Net income in SEK233.97m
- Incorporated1997
- Employees260.00
- LocationSurgical Science Sweden ABDrakegatan 7 A, 3 tr.GOETEBORG 412 50SwedenSWE
- Phone+46 317416560
- Websitehttps://surgicalscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guerbet SA | 9.19bn | 279.14m | 5.60bn | 2.92k | 21.07 | 1.26 | 5.75 | 0.6098 | 1.80 | 1.80 | 62.15 | 29.97 | 0.7997 | 0.5983 | 5.80 | 269,071.90 | 2.26 | 1.40 | 2.96 | 1.86 | 78.01 | 76.02 | 2.82 | 1.82 | 1.21 | 5.62 | 0.5035 | 57.82 | 4.30 | -0.0993 | 158.05 | -12.61 | 5.23 | -10.07 |
| Gen Ilac ve Saglik Urnlr Snyi ve Tcrt AS | 2.74bn | 152.90m | 5.78bn | 622.00 | 37.78 | 3.55 | 23.91 | 2.11 | 1.52 | 1.52 | 27.17 | 16.12 | 1.16 | 6.53 | 7.72 | 13,105,500.00 | 6.45 | 12.39 | 8.91 | 17.53 | 22.07 | 19.06 | 5.55 | 6.95 | 0.9854 | -- | 0.2095 | -- | -23.38 | 47.18 | -28.97 | 147.97 | -- | -- |
| Pharmanutra SpA | 1.17bn | 150.09m | 5.82bn | 105.00 | 38.52 | 9.08 | 33.06 | 4.97 | 1.33 | 1.33 | 10.41 | 5.66 | 0.9426 | 0.3648 | 4.90 | 954,304.80 | 12.07 | 18.39 | 16.12 | 24.80 | 97.56 | 96.36 | 12.81 | 17.77 | 1.83 | 57.61 | 0.3399 | 52.51 | 21.13 | 16.51 | -14.73 | 8.44 | 75.71 | 11.20 |
| Philogen SpA | 270.53m | -72.06m | 6.11bn | 160.00 | -- | 7.94 | -- | 22.57 | -0.1551 | -0.1551 | 0.5747 | 2.25 | 0.1887 | 6.65 | 7.95 | 144,562.50 | -5.03 | -7.32 | -5.56 | -8.36 | 40.04 | 32.04 | -26.64 | -58.66 | 6.84 | -- | 0.1414 | -- | -2.46 | 10.80 | -14.60 | -- | 51.78 | -- |
| Calliditas Therapeutics AB | 1.21bn | -466.18m | 6.67bn | 195.00 | -- | 17.95 | -- | 5.53 | -8.69 | -8.69 | 22.49 | 6.24 | 0.6332 | 5.02 | 9.30 | 6,189,175.00 | -24.46 | -26.46 | -30.27 | -30.27 | 94.99 | -- | -38.63 | -76.59 | 3.08 | -4.44 | 0.7427 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| Basilea Pharmaceutica AG Allschwil | 1.89bn | 125.13m | 6.76bn | 147.00 | 48.89 | -- | 46.83 | 3.58 | 0.8765 | 0.8765 | 13.15 | -0.8335 | 0.7999 | 1.06 | 5.16 | 1,072,340.00 | 5.30 | -1.86 | 7.69 | -2.99 | 83.00 | 83.45 | 6.63 | -2.99 | 2.64 | 2.02 | 1.10 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Pharming Group N.V. | 2.80bn | -117.04m | 6.85bn | 415.00 | -- | 3.07 | 72.18 | 2.45 | -0.0161 | -0.0161 | 0.363 | 0.2837 | 0.5976 | 0.5677 | 7.21 | 577,458.60 | -2.50 | 5.26 | -3.61 | 6.63 | 88.57 | 89.41 | -4.18 | 9.26 | 1.16 | -7.42 | 0.4481 | -- | 19.30 | 9.01 | -177.14 | -- | -13.04 | -- |
| Pharma Mar SA | 1.90bn | 23.70m | 6.92bn | 509.00 | 296.82 | 2.95 | 73.92 | 3.65 | 0.1086 | 0.1086 | 9.10 | 10.92 | 0.4583 | 0.2431 | 6.31 | 318,546.20 | 0.5726 | 18.52 | 0.7699 | 25.89 | 94.30 | 93.76 | 1.25 | 28.87 | 2.14 | -- | 0.17 | -- | -19.45 | 7.77 | -97.70 | -- | 46.37 | -- |
| Boiron SA | 5.77bn | 419.04m | 6.99bn | 2.81k | 16.50 | 1.50 | 10.79 | 1.21 | 2.06 | 2.06 | 28.41 | 22.67 | 0.715 | 1.40 | 5.26 | 175,533.10 | 4.92 | 4.59 | 6.16 | 5.76 | 72.60 | 74.02 | 6.88 | 6.80 | 1.50 | -- | 0.0338 | 53.86 | -7.67 | -3.98 | -19.80 | -9.01 | -17.68 | -1.42 |
| Surgical Science Sweden AB | 882.85m | 233.97m | 7.63bn | 260.00 | 32.58 | 1.76 | 26.34 | 8.64 | 4.59 | 4.59 | 17.32 | 85.16 | 0.1888 | 1.87 | 6.15 | 3,395,585.00 | 5.00 | 4.49 | 5.31 | 4.78 | 69.42 | 70.06 | 26.50 | 23.75 | 3.56 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
| Puretech Health PLC | 36.13m | -712.78m | 8.18bn | 90.00 | -- | 1.63 | -- | 226.29 | -0.1883 | -0.1883 | 0.0096 | 1.36 | 0.0048 | -- | 0.4676 | 29,547.83 | -9.54 | 4.92 | -10.67 | 5.94 | -- | -- | -2,000.84 | 352.67 | -- | -- | 0.0524 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
| Swedencare AB (publ) | 2.41bn | 71.50m | 8.43bn | 552.00 | 117.88 | 1.09 | 21.98 | 3.49 | 0.4505 | 0.4505 | 15.21 | 48.80 | 0.2412 | 2.35 | 9.52 | 4,966,461.00 | 0.7144 | 1.38 | 0.7361 | 1.43 | 55.64 | 55.34 | 2.96 | 5.10 | 1.82 | 2.21 | 0.1746 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
| Gubra A/S | 321.43m | -69.81m | 8.66bn | 219.00 | -- | 11.48 | -- | 26.96 | -2.91 | -2.91 | 13.51 | 29.44 | -- | -- | -- | 936,095.90 | -- | -- | -- | -- | 56.06 | -- | -21.72 | -- | -- | -- | 0.1296 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
| Formycon AG | 908.75m | 886.52m | 8.91bn | 238.00 | 9.19 | 1.38 | 9.81 | 9.81 | 4.70 | 4.70 | 4.84 | 31.32 | 0.0891 | 104.80 | 3.56 | 326,453.80 | 8.69 | 5.87 | 9.33 | 6.33 | 30.00 | 28.54 | 97.55 | 39.76 | 0.9621 | -0.0189 | 0.0176 | 0.00 | 82.83 | 12.47 | 110.59 | 60.58 | 81.87 | -- |
| Eckert & Ziegler SE | 2.88bn | 351.05m | 9.91bn | 1.08k | 27.78 | 3.75 | 19.31 | 3.44 | 1.44 | 1.26 | 11.81 | 10.67 | 0.5812 | 3.28 | 5.63 | 228,923.70 | 7.20 | 8.50 | 8.67 | 10.23 | 47.29 | 48.61 | 12.39 | 14.00 | 2.31 | 12.77 | 0.2008 | 35.09 | 10.74 | 7.84 | -2.84 | 13.22 | 33.82 | -30.12 |
Data as of May 10 2024. Currency figures normalised to Surgical Science Sweden AB's reporting currency: Swedish Krona SEK
39.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 31 Mar 2024 | 4.25m | 8.33% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 3.27m | 6.41% |
| Swedbank Robur Fonder ABas of 29 Feb 2024 | 3.12m | 6.12% |
| Teknik Innovation Norden Fonder ABas of 31 Jul 2023 | 2.70m | 5.29% |
| Fj�rde AP-fondenas of 31 Dec 2023 | 2.68m | 5.24% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 30 Dec 2022 | 1.31m | 2.56% |
| Montanaro Asset Management Ltd.as of 31 Mar 2024 | 728.93k | 1.43% |
| SEB Investment Management ABas of 28 Mar 2024 | 702.48k | 1.38% |
| Amundi Asset Management SA (Investment Management)as of 03 Apr 2024 | 669.53k | 1.31% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 634.60k | 1.24% |
More ▼
Data from 30 Jun 2021 - 30 Apr 2024Source: FactSet Research Systems Inc.
